Key Takeaways The FDA has approved tenecteplase (TNKase; Genentech) for the treatment of acute ischemic stroke (AIS) in adults, according to a Genentech announcement.1 The thrombolytic medicine is an intravenous (IV) tissue plasminogen activator that is clot-dissolving, administered as a single 5-second IV bolus. The company noted that it will be providing a 25-mg vial configuration
The use of semaglutide (Ozempic) was tied to a risk of nonarteritic anterior ischemic optic neuropathy (NAION) in adults with type 2 diabetes, according to a retrospective study. In this review of 37.1 million patients, the incidence rate of NAION among semaglutide users was 14.5 and 8.7 per 100,000 person-years using the sensitive and specific
Researchers from the University of Twente’s TechMed Centre and Radboud University Medical Centre removed blood clots using wireless magnetic robots. This innovation could revolutionise the treatment of life-threatening vascular diseases such as thrombosis. Cardiovascular diseases such as thrombosis are a major health problem worldwide. Worldwide, one in four people die each year from conditions caused
Up to half of all people living with Alzheimer’s Disease in Ireland remain undiagnosed. A new blood test may have the potential to transform patient care, allowing for better diagnosis, earlier interventions and more targeted treatments Researchers at Trinity College, the Tallaght Institute of Memory and Cognition and St James’s Hospital, Dublin are exploring the
A 3D-printed, bioresorbable heart valve promotes tissue regeneration, potentially eliminating the need for repeated surgeries for adult and pediatric heart patients. Every year, more than 5 million people in the U.S. are diagnosed with heart valve disease, but this condition has no effective long-term treatment. When a person’s heart valve is severely damaged by a birth defect,
Researchers at McMaster University have made a groundbreaking discovery in the field of hematology, providing an explanation for spontaneous and unusual bleeding episodes that continue to occur despite treatment with full-dose blood thinners. The discovery, published February 12, 2025 in The New England Journal of Medicine is expected to impact the way doctors test and treat patients
New research, with the caveat of a relatively short follow-up, adds to encouraging data showing an overall low risk of the development of thyroid cancer associated with glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment. However, a notably increased rate of thyroid cancer detections limited only to the first year after drug initiation — but
EPFL researchers have combined injections of a novel hydrogel with systemic osteoporosis drugs in rats, achieving rapid local increases in bone density. The results offer hope for future fracture prevention therapies in osteoporosis patients. Osteoporosis is a disease in which bone resorbs faster than it is formed, gradually weakening its structure over time and leading
Research from the University of Colorado Anschutz Medical Campus reveals drug could potentially help repair vision in those with multiple sclerosis (MS) and other neurological conditions Researchers at the University of Colorado Anschutz Medical Campus have found a promising drug candidate that could help restore vision in individuals with multiple sclerosis (MS) and other neurological conditions that
Women in early menopause treated with zoledronate in just two infusions, 5 years apart, show a significantly reduced risk of sustaining a vertebral fracture and better maintenance of bone mineral density (BMD) over a 10-year period than those receiving just one or no infusions over the period, suggesting the infrequent, early dosing to be a
